The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2019 | Key population-based registry studies in hematological oncology
Magnus Björkholm, MD, PhD, of the Karolinska Institute, Stockholm, Sweden, speaks at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. He discusses key examples of where population-based registry studies have answered questions in the field of hematological oncology, including chronic lymphocytic leukemia, multiple myeloma and myeloproliferative neoplasms.
